Antiarrhythmia agents

Antiarrhythmic Potential of SGLT2 Inhibitors: A Promising Area of Research

Researchers have made significant discoveries about the potential antiarrhythmic benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors, which were originally developed to treat type 2 diabetes. According to recent studies, these inhibitors have shown consistent cardiovascular and renal benefits in large-scale randomized controlled trials. Furthermore, experimental studies suggest that SGLT2 inhibitors